GSK plc Amends 13D Filing for 23andMe Holding Co.

TL;DR

GSK just updated its 23andMe filing. Watch this space.

AI Summary

GSK plc filed an amendment (No. 3) to its Schedule 13D on November 15, 2024, concerning its holdings in 23andMe Holding Co. The filing indicates a change in the reporting person's intentions or beneficial ownership, though specific details of the change are not provided in this excerpt. GSK plc is a pharmaceutical company based in London.

Why It Matters

This amendment signals a potential shift in GSK's stake or strategy regarding 23andMe, which could impact the biotech company's stock performance and future direction.

Risk Assessment

Risk Level: medium — Amendments to Schedule 13D filings often indicate significant changes in a major shareholder's position or intentions, which can lead to market volatility.

Key Players & Entities

• GSK plc (company) — Reporting person
• 23andMe Holding Co. (company) — Subject company
• VG Acquisition Corp. (company) — Former company name for 23andMe Holding Co.
• Virgin Group Acquisition Corp. (company) — Former company name for 23andMe Holding Co.
• Bleecker Street Acquisition Corp. (company) — Former company name for 23andMe Holding Co.
• GLAXOSMITHKLINE PLC (company) — Former company name for GSK plc

FAQ

Key Financial Figures

• $0.0001 — ssuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securiti

Filing Documents

• gsk-sc13da_111224.htm (SC 13D/A) — 49KB
• 0001839882-24-039514.txt ( ) — 51KB

Security and Issuer

Item 1. Security and Issuer . This Amendment No. 3 to Schedule 13D (this “Statement”) amends and supplements the statement on Schedule 13D originally filed on November 4, 2022, as amended on January 20, 2023 and February 9, 2024 (the “Schedule 13D”) with respect to the Class A Common Stock of the Issuer, a Delaware incorporated company. GSK is filing this amendment to disclose its new percentage beneficial ownership in the Issuer, which has been decreased as a result of an increase in the outstanding Class A Common Stock of the Issuer. The Issuer’s principal executive offices are located at 223 N. Mathilda Avenue, Sunnyvale, California 94086.

Identity and Background

Item 2. Identity and Background. The response set forth in Item 2 of the Schedule 13D is hereby amended by deleting Schedule 1 in its entirety and replacing it with Schedule 1 attached.

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer. The response set forth in Items 5 (a) of the Schedule 13D is hereby amended by deleting the previous response in its entirety and replacing it with the following: a. GSK beneficially owns 1,983,025 shares of Class B Common Stock, which represents 9.5% of the 19,011,874 shares of Class A Common Stock of the Issuer outstanding as of October 31, 2024, as reported in the Issuer’s Form 10-Q on November 12, 2024 and the 1,983,025shares of Class B Common Stock held by GGL. CUSIP No. 90138Q306 13D/A3 Page 4 of 6 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct. Date: November 14, 2024 GSK plc By: /s/ Victoria A. Whyte Name: Victoria A. Whyte Title: Authorized Signatory CUSIP No. 90138Q306 13D/A3 Page 5 of 6 Schedule 1 Name Citizenship Board of Directors Sir Jonathan Symonds CBE 79 New Oxford Street London, WC1A 1DG United Kingdom Chair and Company Director British Emma Walmsley 79 New Oxford Street London, WC1A 1DG United Kingdom Executive Director British Julie Brown 79 New Oxford Street London, WC1A 1DG United Kingdom Company Director British Elizabeth McKee Anderson 79 New Oxford Street London, WC1A 1DG United Kingdom Company Director US Charles Bancroft 79 New Oxford Street, London, WC1A 1DG, United Kingdom Company Director US Dr. Hal Barron 79 New Oxford Street London, WC1A 1DG United Kingdom Company Director US Dr. Anne Beal 79 New Oxford Street London, WC1A 1DG England Company Director US Wendy Becker 79 New Oxford Street London, WC1A 1DG United Kingdom Company Director British & US & Italian Dr. Harry (Hal) Dietz 79 New Oxford Street London, WC1A 1DG United Kingdom Company Director US Dr. Jesse Goodman 79 New Oxford Street London,

View Full Filing

View this SC 13D/A filing on SEC EDGAR